2011 Q4 Form 10-Q Financial Statement

#000110465911060121 Filed on November 02, 2011

View on sec.gov

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2010Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	25000	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26733969	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26733969	shares
CY2010Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26880595	shares
CY2010Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26880595	shares
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	119000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-29455000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	29790000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11878000	USD
	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	17912000	USD
CY2010Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14432000	USD
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	99022000	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2011
CY2011Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34113882	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2011-09-30
CY2010Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2010Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15000	USD
CY2010Q3	us-gaap	Costs And Expenses CostsAndExpenses	10067000	USD
CY2010Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10021000	USD
CY2010Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	30000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	26000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-29244000	USD
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9579000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	30230000	USD
CY2010Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	230299000	USD
CY2010Q4	us-gaap	Common Stock Value CommonStockValue	269000	USD
CY2010Q4	us-gaap	Liabilities Liabilities	43095000	USD
CY2010Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2011Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2010Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2011Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
	us-gaap	Sales Revenue Net SalesRevenueNet	335000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	97000	USD
	mblx	Research And Development Revenue ResearchAndDevelopmentRevenue	212000	USD
CY2011Q3	us-gaap	Costs And Expenses CostsAndExpenses	10048000	USD
CY2010Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4161000	USD
CY2010Q3	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	5906000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	986000	USD
CY2010Q3	us-gaap	Sales Revenue Net SalesRevenueNet	46000	USD
CY2010Q3	us-gaap	Revenue From Grants RevenueFromGrants	21000	USD
CY2011Q3	us-gaap	Sales Revenue Net SalesRevenueNet	469000	USD
CY2010Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	107000	USD
CY2010Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26895389	shares
CY2010Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2011Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2010Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2010Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2010Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q3	us-gaap	Liabilities Liabilities	43537000	USD
CY2010Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	36207000	USD
CY2010Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	386000	USD
CY2010Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6395000	USD
CY2010Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1906000	USD
CY2011Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2011Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6957000	USD
CY2010Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	165000	USD
CY2010Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4085000	USD
CY2010Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	239000	USD
CY2010Q4	us-gaap	Assets Assets	66771000	USD
CY2010Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	117000	USD
CY2011Q3	us-gaap	Assets Assets	91407000	USD
CY2010Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2776000	USD
CY2010Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	622000	USD
CY2010Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2010Q4	us-gaap	Assets Current AssetsCurrent	63256000	USD
CY2010Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	846000	USD
CY2010Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	8000	USD
CY2010Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	828000	USD
CY2011Q3	us-gaap	Assets Current AssetsCurrent	73931000	USD
CY2010Q4	us-gaap	Short Term Investments ShortTermInvestments	49048000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12526000	USD
CY2011Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2010Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	66771000	USD
CY2011Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91407000	USD
CY2010Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-206877000	USD
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001121702
	dei	Entity Registrant Name EntityRegistrantName	METABOLIX, INC.
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	73118000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	29000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	646000	USD
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">3. RECENT ACCOUNTING PRONOUNCEMENTS</font></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</font></p> <p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">In June&nbsp;2011, the FASB issued Accounting Standards Update (ASU) No.&nbsp;2011-05, &#147;<i>Comprehensive Income (Topic 220)</i>&#148; (ASU 2011-05). This newly issued accounting standard (1)&nbsp;eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders&#146; equity, and (2)&nbsp;requires the consecutive presentation of the statement of net income and other comprehensive income. The amendments in this ASU do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income nor do the amendments affect how earnings per share is calculated or presented. This ASU is required to be applied retrospectively and is effective for fiscal years and interim periods within those years beginning after December&nbsp;15, 2011, which for Metabolix will be the fiscal year that begins on January&nbsp;1, 2012. As this accounting standard only requires enhanced disclosure, the adoption of this standard will not impact the Company&#146;s financial position or results of operations.</font></p> <p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">In May&nbsp;2011, the FASB issued ASU No.&nbsp;2011-04, &#147;<i>Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S.&nbsp;GAAP and IFRS</i>&#148; (ASU&nbsp;2011-04). This newly issued accounting standard clarifies the application of certain existing fair value measurement guidance and expands the disclosures for fair value measurements that are estimated using significant unobservable (Level&nbsp;3)&nbsp;inputs. This ASU is effective on a prospective basis for annual and interim reporting periods beginning on or after December&nbsp;15, 2011, which for Metabolix will be the fiscal year that begins on January&nbsp;1, 2012. The Company does not expect that adoption of this standard will have a material impact on its financial position or results of operations.</font></p> <p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">On January&nbsp;1, 2011, the Company adopted new authoritative guidance on revenue recognition for multiple-element arrangements. The guidance, which applies to multiple-element arrangements entered into or materially modified on or after January&nbsp;1, 2011, amends the criteria for separating and allocating consideration in a multiple-element arrangement by modifying the fair value requirements for revenue recognition and eliminating the use of the residual method. The fair value of deliverables under the arrangement may be derived using a &#147;best estimate of selling price&#148; if vendor specific objective evidence, or VSOE, and third-party evidence, or TPE, is not available. Deliverables under the arrangement will be separate units of accounting provided (a)&nbsp;a delivered item has value to the customer on a standalone basis; and (b)&nbsp;if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the Company. The Company did not enter into or materially modify any multiple-element arrangements during the nine months ended September&nbsp;30, 2011.</font></p></td></tr></table>
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17392000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	366000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	456000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-620000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-301000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	25000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-5000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3474000	USD
	mblx	Charge For Company Common Stock Match ChargeForCompanyCommonStockMatch	377000	USD
CY2010Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26895389	shares
CY2011Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34088286	shares
CY2011Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34088286	shares
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1203000	USD
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10814000	USD
	mblx	Proceeds From Options And Warrants Exercised ProceedsFromOptionsAndWarrantsExercised	2316000	USD

Files In Submission

Name	View Source	Status
0001104659-11-060121-index-headers.html	Edgar Link	pending
0001104659-11-060121-index.html	Edgar Link	pending
0001104659-11-060121.txt	Edgar Link	pending
0001104659-11-060121-xbrl.zip	Edgar Link	pending
a11-25898_110q.htm	Edgar Link	pending
a11-25898_1ex31d1.htm	Edgar Link	pending
a11-25898_1ex31d2.htm	Edgar Link	pending
a11-25898_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
mblx-20110930.xml	Edgar Link	completed
mblx-20110930.xsd	Edgar Link	pending
mblx-20110930_cal.xml	Edgar Link	unprocessable
mblx-20110930_def.xml	Edgar Link	unprocessable
mblx-20110930_lab.xml	Edgar Link	unprocessable
mblx-20110930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending